Gapping down
In reaction to earnings/guidance:
- SNAP -29.2% (lowers guidance), ANF -19.6%, WKME -6.7% (also announces partnership with Celonis), API -5.8%, DOLE -3.1%, AAP -2.9%, GFL -1.2% (guidance), ATHM -1.1%
Other news:
- INMB -28.5% (FDA places IND application to initiate Phase 2 trial of XPro in patients with Alzheimer's on clinical hold; FDA reuquests more info on manufacturing process)
- PINS -12.7% (in sympathy with weak SNAP guidance)
- TTD -8.6% (in sympathy with weak SNAP guidance)
- FB -7% (in sympathy with weak SNAP guidance)
- MGNI -5.6% (in sympathy with weak SNAP guidance)
- ROKU -5.4% (in sympathy with weak SNAP guidance)
- RIGL -4.5% (Knight Therapeutics enters into exclusive license and supply agreements with Rigel Pharmaceuticals to commercialize fostamatinib in Latin America)
- GOOG -3.7% (in sympathy with weak SNAP guidance)
- TWTR -3.3% (in sympathy with weak SNAP guidance)
- PUBM -3.2% (in sympathy with weak SNAP guidance)
- HEP -3.1% (files for $2 bln mixed securities shelf offering; also files for 59630030 common unit offering by selling shareholders)
- ARKK -2.5% (in sympathy with strong ZM earnings)
Analyst comments:
- RBLX -5% (downgraded to Neutral from Overweight at Atlantic Equities)